drugset / Trial / NCT04176250

Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

NCT04176250

Phase 2 Completed 93 enrolled Gates Medical Research Institute
RandomizedSequentialSingle-blindTreatment

Summary

The purpose of this study is to assess the safety, early bactericidal activity (EBA) and pharmacokinetics of TBA-7371 in adult participants with rifampicin-sensitive tuberculosis and select dose regimen(s) for future studies.

Timeline

Start
2020-01-16
Primary completion
2022-10-05
Completion
2022-10-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ethambutol Small molecule
Comparator Isoniazid Small molecule
Comparator Pyrazinamide Small molecule
Comparator Rifampin Small molecule
Subject TBA-7371 Small molecule 100 mg Oral
Subject TBA-7371 Small molecule 200 mg Oral
Subject TBA-7371 Small molecule 400 mg Oral